Laura K. Richman

4.9k total citations · 1 hit paper
64 papers, 3.6k citations indexed

About

Laura K. Richman is a scholar working on Epidemiology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Laura K. Richman has authored 64 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 18 papers in Oncology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Laura K. Richman's work include Herpesvirus Infections and Treatments (19 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Virus-based gene therapy research (9 papers). Laura K. Richman is often cited by papers focused on Herpesvirus Infections and Treatments (19 papers), Monoclonal and Polyclonal Antibodies Research (14 papers) and Virus-based gene therapy research (9 papers). Laura K. Richman collaborates with scholars based in United States, Germany and United Kingdom. Laura K. Richman's co-authors include Bahija Jallal, Brandon W. Higgs, James M. Wilson, Tamara Goode, Christian Hinderer, Elizabeth L. Buza, Yihong Yao, Peter Bell, Nathan Katz and Cecilia Dyer and has published in prestigious journals such as Science, Journal of Clinical Oncology and Blood.

In The Last Decade

Laura K. Richman

63 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN

2018 561 citations Christian Hinderer, Nathan Katz et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura K. Richman United States	30	1.2k	1.1k	984	885	815	64	3.6k
Carole Yee United States	29	1.3k 1.1×	695 0.6×	1.9k 1.9×	962 1.1×	397 0.5×	59	4.1k
Sunao Sugita Japan	44	1.6k 1.3×	1.2k 1.1×	1.0k 1.0×	137 0.2×	746 0.9×	139	5.7k
Guerrino Meneguzzi France	46	3.3k 2.8×	813 0.7×	811 0.8×	1.0k 1.2×	320 0.4×	155	7.7k
Tobias Alexander Germany	38	453 0.4×	2.2k 2.0×	385 0.4×	343 0.4×	1.2k 1.5×	134	4.4k
James C. Neil United Kingdom	38	2.0k 1.7×	794 0.7×	926 0.9×	1.1k 1.2×	79 0.1×	97	3.8k
Susan Mackem United States	35	3.1k 2.6×	394 0.4×	1.1k 1.1×	1.4k 1.6×	584 0.7×	61	5.1k
Ingrid G. Winkler Australia	34	1.3k 1.1×	1.7k 1.6×	312 0.3×	420 0.5×	159 0.2×	90	4.5k
Antoine Blancher France	38	1.3k 1.1×	1.2k 1.1×	510 0.5×	780 0.9×	159 0.2×	184	5.1k
Dorothea L. Schiller Germany	17	3.2k 2.6×	409 0.4×	559 0.6×	860 1.0×	287 0.4×	18	7.5k
Monique V. Davies United States	27	3.7k 3.1×	469 0.4×	410 0.4×	821 0.9×	272 0.3×	36	5.0k

Countries citing papers authored by Laura K. Richman

Since Specialization

Citations

This map shows the geographic impact of Laura K. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura K. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura K. Richman more than expected).

Fields of papers citing papers by Laura K. Richman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura K. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura K. Richman. The network helps show where Laura K. Richman may publish in the future.

Co-authorship network of co-authors of Laura K. Richman

This figure shows the co-authorship network connecting the top 25 collaborators of Laura K. Richman. A scholar is included among the top collaborators of Laura K. Richman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura K. Richman. Laura K. Richman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Buonato, Janine M., Justin P. Edwards, Liubov Zaritskaya, et al.. (2022). Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. Molecular Cancer Therapeutics. 21(7). 1171–1183. 16 indexed citations

Hinderer, Christian, Nathan Katz, Cecilia Dyer, et al.. (2020). Translational Feasibility of Lumbar Puncture for Intrathecal AAV Administration. Molecular Therapy — Methods & Clinical Development. 17. 969–974. 33 indexed citations

Rothwell, William T., Peter Bell, Laura K. Richman, et al.. (2018). Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice. Cancer Research. 78(21). 6171–6182. 19 indexed citations

Hordeaux, Juliette, Christian Hinderer, Tamara Goode, et al.. (2018). Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques. Molecular Therapy — Methods & Clinical Development. 10. 68–78. 58 indexed citations

Oberst, Michael D., Stacy Fuhrmann, Kathy Mulgrew, et al.. (2014). CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs. 6(6). 1571–1584. 71 indexed citations

Zhu, Wei, Jiaqi Huang, Brandon W. Higgs, et al.. (2014). Abstract 4280: Integrative analyses of multi-omics sequencing data to guide treatment decisions in a patient with double malignancy. Cancer Research. 74(19_Supplement). 4280–4280. 1 indexed citations

Zhang, Jianchun, Binbing Yu, Lanju Zhang, et al.. (2014). Non-Normal Random Effects Models for Immunogenicity Assay Cut Point Determination. Journal of Biopharmaceutical Statistics. 25(2). 295–306. 9 indexed citations

Higgs, Brandon W., Linda Chang, Inna Vainshtein, et al.. (2013). Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti-Interferon-α Receptor Antibody. Clinical Pharmacology & Therapeutics. 93(6). 483–492. 49 indexed citations

Bao, Haifeng, Peter Burke, Jiaqi Huang, et al.. (2013). Circulating Tumor Cells: Application as a Biomarker for Molecular Characterization and Predictor of Survival in an All-Comer Solid Tumor Phase I Clinical Study. PLoS ONE. 8(8). e58557–e58557. 14 indexed citations

10.

Streicher, Katie, Chris Morehouse, Bhargavi Rajan, et al.. (2013). THU0005 Investigating the Plasma Cell Signature in Autoimmune Disease. Annals of the Rheumatic Diseases. 72. A166–A166. 2 indexed citations

11.

Gossage, David, Michel Laviolette, Gail M. Gauvreau, et al.. (2012). Depletion Of Airway Eosinophils By Benralizumab An Anti-IL5 Receptor Alpha Monoclonal Antibody. A3961–A3961. 3 indexed citations

12.

Streicher, Katie, Wei Zhu, Kim Lehmann, et al.. (2011). A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 31(12). 1558–1570. 110 indexed citations

13.

Huang, Jiaqi, Chris Morehouse, Katie Streicher, et al.. (2011). Altered Expression of Insulin Receptor Isoforms in Breast Cancer. PLoS ONE. 6(10). e26177–e26177. 52 indexed citations

14.

Moschos, Stergios J., Cindy Sander, Wenjun Wang, et al.. (2010). Pharmacodynamic (Phase 0) Study Using Etaracizumab in Advanced Melanoma. Journal of Immunotherapy. 33(3). 316–325. 20 indexed citations

15.

Yao, Yihong, Laura K. Richman, Chris Morehouse, et al.. (2008). Type I Interferon: Potential Therapeutic Target for Psoriasis?. PLoS ONE. 3(7). e2737–e2737. 257 indexed citations

16.

Fickel, Joerns, Dietmar Lieckfeldt, Laura K. Richman, et al.. (2002). Comparison of glycoprotein B (gB) variants of the elephant endotheliotropic herpesvirus (EEHV) isolated from Asian elephants (Elephas maximus). Veterinary Microbiology. 91(1). 11–21. 17 indexed citations

17.

Fickel, Joerns, Laura K. Richman, Richard J. Montali, et al.. (2001). A variant of the endotheliotropic herpesvirus in Asian elephants (Elephas maximus) in European zoos. Veterinary Microbiology. 82(2). 103–109. 43 indexed citations

18.

Richman, Laura K., Richard J. Montali, Richard L. Garber, et al.. (1999). Novel Endotheliotropic Herpesviruses Fatal for Asian and African Elephants. Science. 283(5405). 1171–1176. 150 indexed citations

19.

Aquilina, Joseph W., LuAnn McKinney, Anna Pacelli, et al.. (1998). High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. The Prostate. 36(3). 189–193. 32 indexed citations

20.

Kennedy, Melissa, et al.. (1996). Encephalitis associated with a variant of equine herpesvirus 1 in a Thomson's gazelle ( Gazella thomsonii). Journal of Zoo and Wildlife Medicine. 27(4). 533–538. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact